# Non-Opioid Chronic Pain Treatments Vertanical Advances Its Non-Opioid Treatment in Germany By Kalin Ned | Published 2026-06-09 | Marketing Source: Trend Hunter, https://www.trendhunter.com/trends/nonopioid-treatment References: [biospectrumasia](https://www.biospectrumasia.com/news/34/27776/vertanical-secures-first-european-marketing-authorisation-for-exilby-in-chronic-low-back-pain.html)  Vertanical has received marketing authorization in Germany for Exilby — a first-in-class non-opioid treatment for chronic low back pain with a radicular neuropathic component. The product is based on two pivotal Phase 3 trials involving over 1,200 patients that demonstrated significant pain reduction, a favorable tolerability profile, and no evidence of dependence, with a head-to-head comparator study showing superior pain relief and better gastrointestinal tolerability than opioids. Exilby is a standardized full-spectrum extract derived from a proprietary [Cannabis sativa strain](https://www.trendhunter.com/trends/aurora-cannabis), containing a defined mixture of cannabinoids, terpenes, and other bioactive compounds selected specifically for pain modulation. The non-opioid treatment has been granted Breakthrough Therapy Designation by the [U.S. Food and Drug Administration](https://www.trendhunter.com/trends/xtresse-xvie), with a pivotal U.S. Phase 3 trial already underway and a potential New Drug Application planned for 2028. Image Credit: Vertanical ## Trend Insights (Trend Hunter) - Score: 4.8/10 - Popularity: 34% | Activity: 32% | Freshness: 78% - Audience gender: 50% men, 50% women - Primary generations: Gen X - Top markets: North America, Europe ## Categories [Trend Hunter](https://www.trendhunter.com/trends) > [Marketing](https://www.trendhunter.com/marketing) > [Branding](https://www.trendhunter.com/branding) ## Key Themes ### What's Driving This Trend - **Non-opioid Pain Relief:** Regulatory validation of dependence-free chronic pain therapies creates space for analgesic portfolios that challenge opioid incumbents in long-term care. - **Cannabis-derived Pharmaceuticals:** Standardized full-spectrum extracts with defined cannabinoid and terpene profiles signal a shift from wellness cannabis toward clinically validated prescription medicines. - **Evidence-based Neuropathic Care:** Phase 3 data for radicular neuropathic pain highlights commercial potential in targeted treatments for pain subtypes that remain underserved by broad analgesics. ### Who This Affects Most - **Pharmaceuticals:** First-in-class approvals for novel pain compounds create competitive openings for drugmakers seeking safer chronic-use therapies with strong differentiation. - **Pain Management:** Clinics and specialist care networks may see new treatment pathways emerge as non-opioid options demonstrate efficacy, tolerability, and reduced dependence risk. - **Medical Cannabis:** Prescription-grade cannabis formulations backed by pivotal trials expand the sector beyond consumer products into regulated therapeutic markets. ## Related on Trend Hunter - [Exosome Skincare Systems](https://www.trendhunter.com/trends/Exosome-skincare-systems.md) - [Science-Driven Suppositories](https://www.trendhunter.com/trends/ebbtide.md) - [Non-Cannabis Prescription Offerings](https://www.trendhunter.com/trends/starseed-medicinal.md) - [Medicated Cat Foods](https://www.trendhunter.com/trends/vikaly-by-virbac.md) - [Bio-Optimized Pain Relivers](https://www.trendhunter.com/trends/relivaid.md) - [Prescriptive VR Therapy Platforms](https://www.trendhunter.com/trends/myndxr.md) - [Anti-Inflammatory Agent Studies](https://www.trendhunter.com/trends/antiinflammatory-agent.md) - [Regenerative Injectable Treatments](https://www.trendhunter.com/trends/xtresse-xvie.md) - [Non-Invasive Muscle Activation Technologies](https://www.trendhunter.com/trends/muscle-activations.md)